4 commercial payer policies list C86.0. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
4 policies from 2 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of C86.0 |
|---|---|---|
| Pharmacogenetic and Pharmacodynamic Testing | Feb 27, 2024 | Covered |
| Plerixafor | Jan 9, 2024 | Covered |
| Tumor Markers | Mar 5, 2024 | Covered |
| Policy | Effective | Status of C86.0 |
|---|---|---|
| Donor Lymphocyte Infusion for Hematologic Malignancies after Allogeneic Hematopoietic Progenitor Cell Transplantation | Jul 1, 2026 | Covered |